Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.

Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, RIbet C, Bernard C, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Daguenel-Nguyen A, Doppler V, Mariau J, Vicaut E, Klatzmann D.

Ann Rheum Dis. 2019 Feb;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229. Epub 2018 Nov 24.

PMID:
30472651
2.

Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol.

Lorenzon R, Mariotti-Ferrandiz E, Aheng C, Ribet C, Toumi F, Pitoiset F, Chaara W, Derian N, Johanet C, Drakos I, Harris S, Amselem S, Berenbaum F, Benveniste O, Bodaghi B, Cacoub P, Grateau G, Amouyal C, Hartemann A, Saadoun D, Sellam J, Seksik P, Sokol H, Salem JE, Vicaut E, Six A, Rosenzwajg M, Bernard C, Klatzmann D.

BMJ Open. 2018 Aug 30;8(8):e021037. doi: 10.1136/bmjopen-2017-021037.

3.

Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2.

Churlaud G, Abbara C, Vinot PA, Fourcade G, Ritvo PG, Lorenzon R, Rosenzwajg M, Diquet B, Klatzmann D.

J Allergy Clin Immunol. 2018 Oct;142(4):1344-1346.e3. doi: 10.1016/j.jaci.2018.06.006. Epub 2018 Jun 18. No abstract available.

4.

Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 Therapy.

Churlaud G, Pitoiset F, Jebbawi F, Lorenzon R, Bellier B, Rosenzwajg M, Klatzmann D.

Front Immunol. 2015 Apr 15;6:171. doi: 10.3389/fimmu.2015.00171. eCollection 2015.

5.

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.

Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D.

J Autoimmun. 2015 Apr;58:48-58. doi: 10.1016/j.jaut.2015.01.001. Epub 2015 Jan 26.

6.

Kinetic characterization of the Escherichia coli oligopeptidase A (OpdA) and the role of the Tyr(607) residue.

Lorenzon RZ, Cunha CE, Marcondes MF, Machado MF, Juliano MA, Oliveira V, Travassos LR, Paschoalin T, Carmona AK.

Arch Biochem Biophys. 2010 Aug 15;500(2):131-6. doi: 10.1016/j.abb.2010.05.025. Epub 2010 May 27.

PMID:
20513640

Supplemental Content

Loading ...
Support Center